Product Description
Mechanisms of Action: AKR Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Bangladesh | China | India | Korea | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: China Resources Zizhu
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 3: Congenital Disorders of Glycosylation
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| PMM2-CDG | P3 |
Active, not recruiting |
Congenital Disorders of Glycosylation |
2025-02-28 |
66% |